Innate Pharma (NASDAQ:IPHA) Upgraded at BTIG Research

Posted by Tyrone Williams on Mar 14th, 2026

BTIG Research upgraded shares of Innate Pharma (NASDAQ:IPHA – Free Report) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Get Our Latest Stock Analysis on Innate Pharma

Innate Pharma Stock Performance

Shares of NASDAQ:IPHA opened at $1.50 on Wednesday. The stock has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $1.86. Innate Pharma has a 1 year low of $1.40 and a 1 year high of $2.63.

Institutional Investors Weigh In On Innate Pharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in shares of Innate Pharma in the fourth quarter valued at about $162,000. OLD Mission Capital LLC purchased a new position in Innate Pharma in the 4th quarter worth approximately $50,000. Finally, Millennium Management LLC purchased a new position in Innate Pharma in the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

About Innate Pharma

(Get Free Report)

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.